ProQR Therapeutics (PRQR) Short term Debt (2013 - 2025)

ProQR Therapeutics' Short term Debt history runs 13 years deep, the most recent figure standing at $5.7 million for Q4 2025.

• In Q4 2025, Short term Debt rose 15.83% year-over-year to $5.7 million; the TTM figure through Dec 2025 stood at $5.7 million (up 15.83% YoY), while the FY2025 annual figure was $5.7 million, up 15.83% from the prior year.
• Short term Debt came in at $5.7 million for Q4 2025 at ProQR Therapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $43.1 million in Q1 2022 to a low of $19910.1 in Q1 2021.
• A 5-year average of $12.2 million and a median of $4.9 million in 2024 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt sank 99.86% in 2021 and surged 216181.09% in 2022, its largest moves.
• ProQR Therapeutics' Short term Debt stood at $5.5 million in 2021, then tumbled by 53.27% to $2.6 million in 2022, then rose by 23.39% to $3.1 million in 2023, then surged by 55.58% to $4.9 million in 2024, then gained by 15.83% to $5.7 million in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $5.7 million, $4.9 million, and $3.1 million for Q4 2025, Q4 2024, and Q3 2023 respectively.

Peer Comparison